Latest Period
Q2 2026
Security Snapshot
ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) Institutional Ownership
CUSIP: N71542109
13F Institutional Holders and Ownership History from Q3 2014 to Q2 2026
Institutions Reporting
71
Shares (Excl. Options)
60,739,494
Price
$1.86
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, nominal value Euro 0.04 per share
- Symbol
- PRQR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 60,739,494
- Total 13F value
- $112,975,690
- Portfolio coverage rank
- 0%
- Share change
- +25,579,361
- Value change
- +$48,357,242
- Number of holders
- 71
- Shares outstanding
- 141,139,908
- SEC-reported price per share
- $1.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PRQR - ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share is tracked under CUSIP N71542109.
- 71 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 68 to 71 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $56,839,482 to $112,975,690.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 71 institutions filings for Q2 2026.
Security key
N71542109
Latest holder period
Q2 2026
13F holders
71
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
PRQR full holder history
ProQR Therapeutics N.V. SEC filings
ProQR Therapeutics N.V. company facts
ProQR Therapeutics N.V. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP N71542109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PRQR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ELI LILLY & Co | 16% | $40,912,337 | 21,995,880 | ELI LILLY & Co | 26 Jun 2026 | |||
| VAN HERK INVESTMENTS B.V. | 11% | 0% | $28,614,705 | 15,384,250 | 0% | Van Herk Investments B.V. | 27 Jul 2026 | |
| Aberdeen Group plc | 6.3% | $16,614,463 | 8,932,507 | Aberdeen Group plc | 30 Jun 2026 | |||
| Adage Capital Management, L.P. | 6.3% | -18% | $13,467,954 | -$3,060,326 | 6,601,938 | -19% | Adage Capital Management, L.P. | 30 Jun 2025 |
| Privium Fund Management B.V. | 5.2% | 0% | $10,283,683 | 5,528,862 | 0% | PATRICK JOHAN HENDRIK KROL | 15 Jul 2026 |
As of 30 Jun 2026, 71 institutional investors reported holding 60,739,494 shares of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR). This represents 43% of the company’s total 141,139,908 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
41%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.4% | 9,015,897 | +44% | 0.02% | $16,769,568 |
| Aberdeen Group plc | 6.3% | 8,932,507 | +169% | 0.02% | $16,614,463 |
| Affinity Asset Advisors, LLC | 3.9% | 5,543,936 | +126% | 0.5% | $10,311,721 |
| Privium Fund Management B.V. | 3.9% | 5,520,024 | +0.97% | 1.9% | $10,267,245 |
| Ikarian Capital, LLC | 2.4% | 3,425,930 | +130% | 1% | $6,372,230 |
| Woodline Partners LP | 2.3% | 3,277,143 | 0.02% | $6,095,486 | |
| HEIGHTS CAPITAL MANAGEMENT, INC | 2% | 2,762,430 | 1.2% | $5,138,120 | |
| MORGAN STANLEY | 1.3% | 1,767,215 | +36% | 0% | $3,287,020 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.2% | 1,757,458 | 0.47% | $3,268,872 | |
| Kynam Capital Management, LP | 1.1% | 1,566,317 | 0% | 0.16% | $2,913,350 |
| DAFNA Capital Management LLC | 1.1% | 1,530,361 | -2.4% | 0.54% | $2,846,471 |
| Squadron Capital Management LLC | 1.1% | 1,511,496 | 0.96% | $2,811,383 | |
| 683 Capital Management, LLC | 0.99% | 1,393,067 | 0.24% | $2,591,104 | |
| CITADEL ADVISORS LLC | 0.84% | 1,184,314 | +68% | 0% | $2,202,824 |
| PLATINUM INVESTMENT MANAGEMENT LTD | 0.82% | 1,159,428 | -6.2% | 0.53% | $2,156,536 |
| TWO SIGMA INVESTMENTS, LP | 0.81% | 1,138,715 | +24% | 0% | $2,118,010 |
| Eversept Partners, LP | 0.72% | 1,022,265 | 0.1% | $1,901,413 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.67% | 948,736 | +167% | 0.03% | $1,764,649 |
| DIADEMA PARTNERS LP | 0.66% | 926,016 | +414% | 0.65% | $1,722,390 |
| UBS Group AG | 0.45% | 639,243 | +109% | 0% | $1,188,992 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.44% | 620,000 | 0% | 0% | $1,153,000 |
| M28 Capital Management LP | 0.42% | 599,793 | 0% | 2.4% | $1,115,615 |
| RAYMOND JAMES FINANCIAL INC | 0.4% | 571,073 | +4.6% | 0% | $1,062,196 |
| Lynx1 Capital Management LP | 0.37% | 521,413 | +661% | 0.11% | $969,828 |
| JANE STREET GROUP, LLC | 0.32% | 455,104 | +1267% | 0% | $846,493 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
48
Latest
Q2 2026
Rows shown
1-25 of 48
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 60,739,494 | $112,975,690 | +$48,357,242 | $1.86 | 71 |
| 2026 Q1 | 35,086,369 | $56,839,482 | -$4,101,306 | $1.62 | 68 |
| 2025 Q4 | 37,155,466 | $75,053,440 | -$2,280,903 | $2.02 | 65 |
| 2025 Q3 | 37,542,716 | $79,967,112 | -$6,233,021 | $2.13 | 63 |
| 2025 Q2 | 40,456,202 | $82,379,793 | -$1,567,785 | $2.04 | 61 |
| 2025 Q1 | 41,291,570 | $54,918,956 | -$5,787,635 | $1.33 | 63 |
| 2024 Q4 | 44,407,421 | $117,680,021 | +$75,460,221 | $2.65 | 74 |
| 2024 Q3 | 17,443,866 | $31,743,198 | +$264,549 | $1.82 | 45 |
| 2024 Q2 | 17,290,486 | $28,649,850 | -$212,174 | $1.66 | 47 |
| 2024 Q1 | 17,387,392 | $39,773,390 | -$2,337,680 | $2.29 | 48 |
| 2023 Q4 | 18,391,369 | $36,955,484 | -$454,962 | $1.98 | 46 |
| 2023 Q3 | 18,716,181 | $24,328,704 | -$3,600,695 | $1.30 | 45 |
| 2023 Q2 | 21,135,686 | $34,237,327 | -$2,196,851 | $1.62 | 50 |
| 2023 Q1 | 22,322,571 | $47,544,921 | +$11,107,713 | $2.13 | 54 |
| 2022 Q4 | 16,678,999 | $59,949,585 | -$4,474,620 | $3.70 | 44 |
| 2022 Q3 | 21,236,882 | $15,861,034 | -$760,592 | $0.74 | 42 |
| 2022 Q2 | 22,126,805 | $17,208,344 | -$8,963,813 | $0.78 | 47 |
| 2022 Q1 | 31,740,344 | $28,730,297 | -$92,041,029 | $0.91 | 56 |
| 2021 Q4 | 45,445,352 | $364,779,631 | +$6,635,516 | $8.01 | 72 |
| 2021 Q3 | 39,831,678 | $333,392,000 | +$12,212,303 | $8.37 | 65 |
| 2021 Q2 | 38,480,445 | $259,361,000 | -$31,879,222 | $6.74 | 61 |
| 2021 Q1 | 43,321,891 | $286,357,000 | +$115,578,874 | $6.61 | 63 |
| 2020 Q4 | 26,413,704 | $110,936,100 | -$6,602,420 | $4.20 | 46 |
| 2020 Q3 | 19,690,795 | $94,319,000 | -$5,245,378 | $4.79 | 21 |
| 2020 Q2 | 29,107,854 | $176,974,000 | -$802,484 | $6.08 | 43 |